These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 10211091)

  • 1. Thoracic radiation therapy before autologous bone marrow transplantation in relapsed or refractory Hodgkin's disease. PMH Lymphoma Group, and the Toronto Autologous BMT Group.
    Tsang RW; Gospodarowicz MK; Sutcliffe SB; Crump M; Keating A
    Eur J Cancer; 1999 Jan; 35(1):73-8. PubMed ID: 10211091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose etoposide and melphalan, and autologous bone marrow transplantation for patients with advanced Hodgkin's disease: importance of disease status at transplant.
    Crump M; Smith AM; Brandwein J; Couture F; Sherret H; Sutton DM; Scott JG; McCrae J; Murray C; Pantalony D
    J Clin Oncol; 1993 Apr; 11(4):704-11. PubMed ID: 8478664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center eight-year study of 155 patients.
    Chopra R; McMillan AK; Linch DC; Yuklea S; Taghipour G; Pearce R; Patterson KG; Goldstone AH
    Blood; 1993 Mar; 81(5):1137-45. PubMed ID: 8443375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose chemotherapy with or without total body irradiation followed by autologous bone marrow and/or peripheral blood stem cell transplantation for patients with relapsed and refractory Hodgkin's disease: results in 85 patients with analysis of prognostic factors.
    Nademanee A; O'Donnell MR; Snyder DS; Schmidt GM; Parker PM; Stein AS; Smith EP; Molina A; Stepan DE; Somlo G
    Blood; 1995 Mar; 85(5):1381-90. PubMed ID: 7858268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autologous transplantation in poor risk Hodgkin's disease using high dose melphalan/etoposide conditioning with non-cryopreserved marrow rescue. The Newcastle and Northern Region Lymphoma Group.
    Taylor PR; Jackson GH; Lennard AL; Lucraft H; Proctor SJ
    Br J Cancer; 1993 Feb; 67(2):383-7. PubMed ID: 8431371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease before intensive therapy and autologous bone marrow transplantation.
    Colwill R; Crump M; Couture F; Danish R; Stewart AK; Sutton DM; Scott JG; Sutcliffe SB; Brandwein JM; Keating A
    J Clin Oncol; 1995 Feb; 13(2):396-402. PubMed ID: 7844600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single high-dose etoposide and melphalan with non-cryopreserved autologous marrow rescue as primary therapy for relapsed, refractory and poor-prognosis Hodgkin's disease.
    Seymour LK; Dansey RD; Bezwoda WR
    Br J Cancer; 1994 Sep; 70(3):526-30. PubMed ID: 8080741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of relapsed and refractory Hodgkin's disease with high dose chemotherapy and autologous bone marrow transplantation.
    Brice P; Gisselbrecht C; Ferme C; Lepage E; Baruchel A; Marolleau JP; Gerota O; Boiron M
    Nouv Rev Fr Hematol (1978); 1991; 33(3):267-72. PubMed ID: 1956765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose therapy and autologous bone marrow transplantation for relapsed/refractory Hodgkin's disease: the impact of involved field radiotherapy on patterns of failure and survival.
    Poen JC; Hoppe RT; Horning SJ
    Int J Radiat Oncol Biol Phys; 1996 Aug; 36(1):3-12. PubMed ID: 8823253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Favorable outcome of patients with relapsed or refractory Hodgkin's disease treated with high-dose chemotherapy and stem cell rescue at the time of maximal response to conventional salvage therapy (Dex-BEAM).
    Josting A; Kàtay I; Rueffer U; Winter S; Tesch H; Engert A; Diehl V; Wickramanayake PD
    Ann Oncol; 1998 Mar; 9(3):289-95. PubMed ID: 9602263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Salvage chemotherapy with mini-BEAM for relapsed or refractory non-Hodgkin's lymphoma prior to autologous bone marrow transplantation.
    Girouard C; Dufresne J; Imrie K; Stewart AK; Brandwein J; Prince HM; Pantolony D; Keating A; Crump M
    Ann Oncol; 1997 Jul; 8(7):675-80. PubMed ID: 9296221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Salvage chemotherapy with mini-BEAM for relapsed or refractory Hodgkin's disease prior to autologous peripheral blood stem cell transplantation.
    Fernández-Jiménez MC; Canales MA; Ojeda E; de Bustos JG; Aguado MJ; Hernández-Navarro F
    Haematologica; 1999 Nov; 84(11):1007-11. PubMed ID: 10553161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation in patients with lymphoid malignancies who have received dose-limiting radiation therapy.
    Weaver CH; Appelbaum FR; Petersen FB; Clift R; Singer J; Press O; Bensinger W; Bianco J; Martin P; Anasetti C
    J Clin Oncol; 1993 Jul; 11(7):1329-35. PubMed ID: 8315430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma.
    Mills W; Chopra R; McMillan A; Pearce R; Linch DC; Goldstone AH
    J Clin Oncol; 1995 Mar; 13(3):588-95. PubMed ID: 7884420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose carmustine, etoposide, and cisplatin and autologous bone marrow transplantation for relapsed and refractory lymphoma.
    Lazarus HM; Crilley P; Ciobanu N; Creger RJ; Fox RM; Shina DC; Bulova SI; Gucalp R; Cooper BW; Topolsky D
    J Clin Oncol; 1992 Nov; 10(11):1682-9. PubMed ID: 1403051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial.
    Linch DC; Winfield D; Goldstone AH; Moir D; Hancock B; McMillan A; Chopra R; Milligan D; Hudson GV
    Lancet; 1993 Apr; 341(8852):1051-4. PubMed ID: 8096958
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autologous bone marrow transplantation for patients with relapsed Hodgkin's disease.
    Armitage JO; Bierman PJ; Vose JM; Anderson JR; Weisenburger DD; Kessinger A; Reed EC; Vaughan WP; Coccia PF; Purtilo DT
    Am J Med; 1991 Dec; 91(6):605-11. PubMed ID: 1750430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of intensive therapy and autologous blood and marrow transplantation for chemotherapy-sensitive relapsed and primary refractory non-Hodgkin's lymphoma: identification of major prognostic groups.
    Prince HM; Imrie K; Crump M; Stewart AK; Girouard C; Colwill R; Brandwein J; Tsang RW; Scott JG; Sutton DM; Pantalony D; Carstairs K; Sutcliffe SB; Keating A
    Br J Haematol; 1996 Mar; 92(4):880-9. PubMed ID: 8616081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non-Hodgkin's lymphoma: a dose-finding study.
    Wheeler C; Antin JH; Churchill WH; Come SE; Smith BR; Bubley GJ; Rosenthal DS; Rappaport JM; Ault KA; Schnipper LE
    J Clin Oncol; 1990 Apr; 8(4):648-56. PubMed ID: 2313334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease.
    Reece DE; Barnett MJ; Connors JM; Fairey RN; Fay JW; Greer JP; Herzig GP; Herzig RH; Klingemann HG; LeMaistre CF
    J Clin Oncol; 1991 Oct; 9(10):1871-9. PubMed ID: 1919637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.